Arcturus Therapeutics

Arcturus Therapeutics is a messenger RNA medicines company
Arcturus Therapeutics has built a multicultural team, based in San Diego, CA, USA
We have an exciting COVID-19 vaccine candidate that we hope will make a positive difference in the pandemic
See our team describe what it means for them to help get a vaccine to protect people around the world-no matter where you are from
A
S
L
https://arcturusrx.com/wp-content/uploads/2023/01/JoePayne_LanguageProficiency_V3_1.mp4,GqH6_3YbPE8
arabic
(عربى)
https://arcturusrx.com/wp-content/uploads/2023/01/MaherA_LanguageProficiency_V3_1.mp4,5UG1sJAhn9c
chinese
(中文)
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_BelleBao.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/BelleBao_LanguageProficiency__V3_1.mp4,AYmnmwhc4Sk
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_HowardYu.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/HowardYu_LanguageProficiency_V3_1.mp4,Y1CtyRPFaX0
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_YurongGuo.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/YurongGuo_LanguageProficiency_V3_1.mp4,C2b3_eHyRhU
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_XuefengGuo.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/XuefengGuo_LanguageProficiency_V3_1.mp4,2xl9qMbKY7E
english
(British)
https://arcturusrx.com/wp-content/uploads/2023/01/MikeHodges_LanguageProficiency_V3_1.mp4,I3h8XBCkHNw
farsi
(فارسی)
https://arcturusrx.com/wp-content/uploads/2023/01/NedaSafarzadeh_LanguageProficiency_V5.mp4,icGbloTCg7U
french
(Français)
https://arcturusrx.com/wp-content/uploads/2023/01/NadjaEl-mecharrafie_LanguageProficiency_V3_1.mp4,82m_php4iVY
german
(deutsch)
https://arcturusrx.com/wp-content/uploads/2023/01/LisaKieweg-Thompson_LanguageProficiency_V3_1.mp4,LtWT-TiVJDE
hebrew
(עִברִית)
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_NoaScott.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/NoaScott_LanguageProficiency_V3_1.mp4,rY5LNfJEDT8
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_TamarGrossman.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/TamarGrossman_LanguageProficiency_V3_1.mp4,3Yx6MAJaQwE
hindi
(हिन्दी)
https://arcturusrx.com/wp-content/uploads/2023/01/PriyaKarmali_LanguageProficiency_V3_1.mp4,JkcPJYFUTw8
italian
(italiano)
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_CristianoSacchetti.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/CristianoSacchetti_LanguageProficiency_V3_1.mp4,z0MvPIms_oc
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_GiulioCattarossi.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/GiulioCattarossi_LanguageProficiency_V3_1.mp4,tR0Jm6TfJd0
Japanese
(日本語)
https://arcturusrx.com/wp-content/uploads/2023/01/Kiyoshi_Tachikawa_v2.mp4,IOChrMthw7s
korean
(한국어)
https://arcturusrx.com/wp-content/uploads/2023/01/JaeHeonKim_LanguageProficiency_V3_1.mp4,_tAwdiqPqUk
portuguese
(Português)
https://arcturusrx.com/wp-content/uploads/2023/01/RamonDiazTrelles_LanguageProficiency_V3_1.mp4,nZGMDeB9DMo
spanish
(español)
https://arcturusrx.com/wp-content/uploads/2023/01/CarlosPerezGarcia_LanguageProficiency__V3_1.mp4,UacjnjowMyQ
vietnamese
(Tiếng Việt)
https://arcturusrx.com/wp-content/uploads/2023/01/HannahHuynh_LanguageProficiency_V3_1.mp4,J4A2Qf6T4OE

Clinical Trials

LunairCF is a clinical trial investigating the use of mRNA therapy (also known as ARCT-032) as an alternative to treat Cystic Fibrosis.
LEARN MORE
The mRNA in LUNAR-OTC (also known as ARCT-810) is designed to be a template for making OTC enzyme. Arcturus uses its lipid nanoparticle technology, called LUNAR® to deliver the mRNA template for OTC to the liver, the place where the OTC enzyme is made.
LEARN MORE

News & Events

May 26, 2026
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
May 7, 2026
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
April 27, 2026
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
March 5, 2026
Arcturus Therapeutics to Attend Upcoming Investor Conference
March 3, 2026
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
February 17, 2026
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
January 8, 2026
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
November 24, 2025
Arcturus Therapeutics to Attend Upcoming Investor Conference
November 10, 2025
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress
November 4, 2025
Arcturus Therapeutics to Attend Upcoming Investor Conferences
October 28, 2025
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025
October 22, 2025
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
August 26, 2025
Arcturus Therapeutics to Attend Upcoming Investor Conferences
August 11, 2025
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress
July 24, 2025
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
July 23, 2025
Arcturus Therapeutics to Attend Upcoming Investor Conferences
June 30, 2025
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program
June 23, 2025
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency
May 29, 2025
Arcturus Therapeutics to Attend Upcoming Investor Conferences
May 12, 2025
Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress

STARR® Technology

VideoScaler

LUNAR® Mechanism of Delivery

VideoScaler